56 tracked 13F filers disclose a position in SRZN as of the latest SEC 13F filings, a combined $238.6M in reported value. Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
| # | Fund | Position value | Shares | Last move | As of | History |
|---|---|---|---|---|---|---|
| 1 | TCG Crossover Management, LLC | $42.9M | 1.5M | ▲New +1.5M sh | Q1 2026 | |
| 2 | BAKER BROS. ADVISORS LP | Withheld | 833K | —Held | Q1 2026 | |
| 3 | Boxer Capital Management, LLC | $22.3M | 766K | ▲+84% Added · +350K sh | Q1 2026 | |
| 4 | MILLENNIUM MANAGEMENT LLC | $21.3M | 731K | ▲+1.4% Added · +10K sh | Q1 2026 | |
| 5 | LMR Partners LLP | Withheld | 672K | —Held | Q1 2026 | |
| 6 | Venrock Adviser, LLC | $18.4M | 633K | —Held | Q1 2026 | |
| 7 | STEMPOINT CAPITAL LP | $13.5M | 526K | ▼−15% Reduced · −94K sh | Q1 2026 | |
| 8 | BRAIDWELL LP | $11.5M | 396K | ▼−16% Reduced · −74K sh | Q1 2026 | |
| 9 | PERCEPTIVE ADVISORS LLC | $6.7M | 396K | ▲New +396K sh | Q1 2026 | |
| 10 | 5AM Venture Management, LLC | $11.3M | 388K | —Held | Q1 2026 | |
| 11 | Kalehua Capital Management LLC | $11.2M | 385K | —Held | Q1 2026 | |
| 12 | Vestal Point Capital, LP | $9.9M | 339K | ▲New +339K sh | Q1 2026 | |
| 13 | Vivo Capital, LLC | $7.6M | 260K | —Held | Q1 2026 | |
| 14 | Woodline Partners LP | $6.6M | 228K | ▼−1.2% Reduced · −3K sh | Q1 2026 | |
| 15 | BALYASNY ASSET MANAGEMENT L.P. | $5.9M | 204K | ▲+7.0% Added · +13K sh | Q1 2026 | |
| 16 | Ikarian Capital, LLC | $5.0M | 173K | ▲+163% Added · +107K sh | Q1 2026 | |
| 17 | ACUTA CAPITAL PARTNERS, LLC | $5.0M | 173K | ▼−3.1% Reduced · −6K sh | Q1 2026 | |
| 18 | VANGUARD CAPITAL MANAGEMENT LLC | $4.9M | 169K | →First observed position No prior filed position | Q1 2026 | |
| 19 | DEERFIELD MANAGEMENT COMPANY, L.P. | Withheld | 167K | —Held | Q1 2026 | |
| 20 | ArrowMark Colorado Holdings LLC | Withheld | 163K | —Held | Q1 2026 | |
| 21 | AMERIPRISE FINANCIAL INC | $4.7M | 160K | ▲+143% Added · +94K sh | Q1 2026 | |
| 22 | REGENTS OF THE UNIVERSITY OF CALIFORNIA | $3.9M | 133K | —Held | Q1 2026 | |
| 23 | ADAGE CAPITAL PARTNERS GP, L.L.C. | $2.6M | 89K | —Held | Q1 2026 | |
| 24 | Euclidean Capital LLC | $2.6M | 88K | —Held | Q1 2026 | |
| 25 | FRED ALGER MANAGEMENT, LLC | $2.1M | 72K | ▼−28% Reduced · −28K sh | Q1 2026 |
Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
Last quarter, 10 funds opened a new position in SRZN and 8 added to an existing one, while 7 reduced and 0 exited entirely — based on 13F filings from active, signal-eligible managers (passive index funds and other mechanical holders are excluded from this count).
| Company | Co-held by | Combined value |
|---|---|---|
| REVOLUTION MEDICINES INCRVMD | 13 funds | $853.7M |
| BOSTON SCIENTIFIC CORPBSX | 12 funds | $535.5M |
| COGENT BIOSCIENCES INCCOGT | 12 funds | $481.9M |
| BIOGEN INCBIIB | 12 funds | $290.5M |
| AMAZON.COM INCAMZN | 11 funds | $4.4B |
| ABIVAX SA-ADRABVX | 11 funds | $1.2B |
| APOGEE THERAPEUTICS INCAPGE | 11 funds | $1.1B |
| INTUITIVE SURGICAL INCISRG | 11 funds | $1.1B |
| UNITEDHEALTH GROUP INCUNH | 11 funds | $1.0B |
| ELI LILLY & COLLY | 11 funds | $803.5M |
| ELEVANCE HEALTH INCELV | 11 funds | $559.5M |
| DIANTHUS THERAPEUTICS INCDNTH | 11 funds | $523.6M |
Ranked by how many of SRZN's institutional holders also hold each name, a cross-fund conviction signal.
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| May 4, 2026 | Li Yang | Exec. Vice President, Research | Sell (S) | 2K | $53K |
| May 4, 2026 | Parker Craig C | Chief Executive Officer, Director | Sell (S) | 5K | $151K |
| May 4, 2026 | Williams Charles O | Chief Operating Officer | Sell (S) | 2K | $68K |
| Mar 24, 2026 | TCG Crossover Fund II, L.P. | 10% Owner | Buy (P) | 53K | $1.3M |
| Mar 24, 2026 | TCG Crossover Fund II, L.P. | 10% Owner | Buy (P) | 53K | $1.3M |
| Mar 23, 2026 | TCG Crossover Fund II, L.P. | 10% Owner | Buy (P) | 8K | $190K |
| Mar 23, 2026 | TCG Crossover Fund II, L.P. | 10% Owner | Buy (P) | 8K | $190K |
| Mar 16, 2026 | TCG Crossover Fund II, L.P. | 10% Owner | Buy (P) | 595 | $15K |
| Mar 16, 2026 | TCG Crossover Fund II, L.P. | 10% Owner | Buy (P) | 595 | $15K |
| Mar 13, 2026 | TCG Crossover Fund II, L.P. | 10% Owner | Buy (P) | 18K | $441K |
| Mar 13, 2026 | TCG Crossover Fund II, L.P. | 10% Owner | Buy (P) | 18K | $441K |
| Mar 12, 2026 | TCG Crossover Fund II, L.P. | 10% Owner | Buy (P) | 6K | $155K |
This stock page is the public Follow view. For one current, evidence-backed answer, use capital_change_brief through REST or MCP. It compares tracked 13F changes with qualifying Form 4 activity and cites the SEC evidence.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/stocks/SRZN/capital-change-brief"
Use Arkolith's capital_change_brief for SRZN. Tell me what changed, whether insider activity corroborates it, and cite the SEC evidence.
13F holdings + Form 4 insider transactions + end-of-day price history + the live filing stream, joined for SRZN. Filings are public domain, sourced to SEC EDGAR; price series derived from end-of-day closes.